ACEPODIA
LIVE

Serial Number

98044259

Owner

Acepodia Biotechnologies Ltd.

Attorney

Evan R. Witt

First Use Date

May 22, 2023

Filing Date

Jun 15, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ACEPODIA Trademark

Serial Number: 98044259 • Registration: 8137873

ACEPODIA is a trademark filed by Acepodia Biotechnologies Ltd. on June 15, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Acepodia Biotechnologies Ltd. (5 trademarks)

17F.-7, No. 99, Sec. 1
New Taipei City 22175 , TW

Entity Type: 03

Trademark Details

Filing Date

June 15, 2023

Registration Date

February 10, 2026

First Use Anywhere

May 22, 2023

First Use in Commerce

May 22, 2023

Published for Opposition

April 16, 2024

Goods & Services

Biological preparations for use in cell cultures for medical or therapeutic purposes; Biological tissue cultures for medical purposes; Medicinal preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for human purposes; Drugs, namely, pharmaceuticals for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Cells for clinical, medical, veterinary, or therapeutic purposes or use; Cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, for clinical, medical, veterinary, or therapeutic purposes; Therapeutic products derived from cells or cell-derived preparations, namely, natural killer cells, gamma delta T cell, and other immune cell, for clinical, medical, veterinary, or therapeutic purposes; Kits comprised of cells and reagents and also containing related instructions for clinical, medicinal, veterinary, or therapeutic purposes or use; Kits comprised of cell-derived preparations, namely, natural killer cell, gamma delta T cell, and other immune cell-derived preparations and reagents and also containing related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use; Pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for targeting tissues based on select tissue markers and ligands, or for the purpose of binding ligands using engineered proteins and receptors; Pharmaceuticals, namely, pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for use in the prevention and treatment of cancer, tumors, hematologic disease, solid cancers, hyperproliferative disease, autoimmune disease, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, immune disease or disorder, and inflammation and inflammatory diseases and in cellular transplants; Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic peptide, therapeutic proteins, and therapeutic nucleic acids for human use for the treatment and prevention of cancer, tumors, autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Pharmaceutical preparations or pharmaceutical products, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers; Pharmaceutical preparations, biological preparations, and therapeutic agents to modulate cell function or cell fate; Biological preparations and therapeutic agents used for medical cell therapy, adoptive immunotherapy, or other immunotherapy; Therapeutic cell preparation based on NK cells (natural killer cells), gamma delta T cell, other immune cell, or other cell for the treatment of cancer, tumors, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, auto-immune diseases, and inflammatory and immune disorders; Bio-engineered component for a therapeutic material, namely, cell lines based on NK cells (natural killer cells), gamma delta T cell, or other immune cell used for medical or clinical use used for immunotherapy

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 10, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 10, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 21, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 21, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 29, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 4, 2025 AITU
USE AMENDMENT FILED
Jun 10, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 10, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 26, 2024 EX1G
SOU EXTENSION 1 FILED
Nov 26, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 26, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 11, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 8, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 8, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 8, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 8, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 8, 2024 CNEA
ASSIGNED TO EXAMINER
Mar 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 19, 2023 NWOS
NEW APPLICATION ENTERED
Jun 19, 2023 NWAP